12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lucentis ranibizumab: Phase III data

Top-line data from the double-blind, U.S. Phase III RISE trial in 377 patients showed that monthly Lucentis met the primary endpoint of a significantly greater proportion of patients who gained >=15 letters in BCVA from baseline to 24 months on the ETDRS eye chart vs. sham control. Patients received monthly 0.3 or 0.5 mg...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >